News Briefs: Boehringer Ingelheim Launched Unbranded Interchangeable Humira Biosimilar
-
Oct 12, 2023
Boehringer Ingelheim’s adalimumab-adbm interchangeable biosimilar is now available at an 81% discount to its reference drug, AbbVie Inc.’s Humira (adalimumab), the manufacturer said Oct. 2. In early July, the company launched a branded version of the agent, Cyltezo, at a 5% discount. Both are citrate-free formulations available in various strengths for multiple inflammatory conditions.
Takeda Pharmaceuticals U.S.A., Inc. will voluntarily withdraw Exkivity (mobocertinib) after the Phase III EXCLAIM-2 confirmatory trial did not meet its primary endpoint, the company disclosed Oct. 2. The FDA gave the kinase inhibitor accelerated approval on Sept. 15, 2021, for the treatment of adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The company says it made the decision in consultation with the FDA and is working with the agency on withdrawal timing. It also is working with other regulatory agencies to withdraw the drug globally. In the meantime, Takeda says it is working to make sure that people receiving Exkivity can maintain access to the medication.
Read more
© 2024 MMIT
Related Posts
-
![]()
Sep 14
News Briefs: Groups Sue HHS Over Lost Coverage of Certain Medicare Part B Drugs
Read more -
![]()
Aug 10
News Briefs: Sen. Mike Lee Reintroduced Biosimilar Red Tape Elimination Act
Read more -
![]()
Jul 13
News Briefs: Genentech Will Voluntarily Withdraw Gavreto’s RET-Mutant Thyroid Cancer Indication
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.